PL445162A1 - Sposób zwiększania rozpuszczalności kofeiny w roztworach wodnych - Google Patents

Sposób zwiększania rozpuszczalności kofeiny w roztworach wodnych

Info

Publication number
PL445162A1
PL445162A1 PL445162A PL44516223A PL445162A1 PL 445162 A1 PL445162 A1 PL 445162A1 PL 445162 A PL445162 A PL 445162A PL 44516223 A PL44516223 A PL 44516223A PL 445162 A1 PL445162 A1 PL 445162A1
Authority
PL
Poland
Prior art keywords
caffeine
increasing
solubility
production
aqueous solutions
Prior art date
Application number
PL445162A
Other languages
English (en)
Other versions
PL249501B1 (pl
Inventor
Dorota Ziółkowska
Oleksandr Shyichuk
Original Assignee
Politechnika Bydgoska Im. Jana I Jędrzeja Śniadeckich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Politechnika Bydgoska Im. Jana I Jędrzeja Śniadeckich filed Critical Politechnika Bydgoska Im. Jana I Jędrzeja Śniadeckich
Priority to PL445162A priority Critical patent/PL249501B1/pl
Publication of PL445162A1 publication Critical patent/PL445162A1/pl
Publication of PL249501B1 publication Critical patent/PL249501B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Botany (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Birds (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

Przedmiotem zgłoszenia jest sposób zwiększenia rozpuszczalności kofeiny w roztworach wodnych. Sposób ma zastosowanie w przemyśle farmaceutycznym do produkcji leków w sprayu dozowanych doustnie oraz do produkcji kosmetyków o charakterze leczniczym oraz w przemyśle spożywczym do przygotowania roztworów technologicznych w produkcji napojów energetycznych. Sposób zwiększenia rozpuszczalności kofeiny w wodzie, polega na tym, że do zawiesiny kofeiny w wodzie dodaje się karagen w dawce zależnej od typu karagenu i stężenia kofeiny w roztworze, a następnie roztwór ogrzewa się do 40 - 60 stopni Celsjusza i miesza do pełnego rozpuszczenia składników, po czym chłodzi do temperatury pokojowej.
PL445162A 2023-06-06 2023-06-06 Sposób zwiększania rozpuszczalności kofeiny w roztworach wodnych PL249501B1 (pl)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL445162A PL249501B1 (pl) 2023-06-06 2023-06-06 Sposób zwiększania rozpuszczalności kofeiny w roztworach wodnych

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL445162A PL249501B1 (pl) 2023-06-06 2023-06-06 Sposób zwiększania rozpuszczalności kofeiny w roztworach wodnych

Publications (2)

Publication Number Publication Date
PL445162A1 true PL445162A1 (pl) 2024-12-09
PL249501B1 PL249501B1 (pl) 2026-05-04

Family

ID=93799867

Family Applications (1)

Application Number Title Priority Date Filing Date
PL445162A PL249501B1 (pl) 2023-06-06 2023-06-06 Sposób zwiększania rozpuszczalności kofeiny w roztworach wodnych

Country Status (1)

Country Link
PL (1) PL249501B1 (pl)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5900416A (en) * 1996-02-01 1999-05-04 Anthea Enterprises Incorporated Aqueous caffeine dosage forms
KR20170138175A (ko) * 2016-06-07 2017-12-15 김선화 난용성약물 천연 커피카페인의 가용화 기술을 이용한 탈모방지 화장품 조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5900416A (en) * 1996-02-01 1999-05-04 Anthea Enterprises Incorporated Aqueous caffeine dosage forms
KR20170138175A (ko) * 2016-06-07 2017-12-15 김선화 난용성약물 천연 커피카페인의 가용화 기술을 이용한 탈모방지 화장품 조성물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A. SHALMASHI AND F. GOLMOHAMMAD:: "Lat. Am. appl. res. vol.40 no.3 Bahía Blanca jul. 2010", SOLUBILITY OF CAFFEINE IN WATER, ETHYL ACETATE, ETHANOL, CARBON TETRACHLORIDE, METHANOL, CHLOROFORM, DICHLOROMETHANE, AND ACETONE BETWEEN 298 AND 323 K, *
L. LOMBA, A. POLO, J. ALEJANDRE, N. MARTÍNEZ, B. GINER:: "Journal of Drug Delivery Science and Technology, Volume 79, January 2023, 104010", SOLUBILITY ENHANCEMENT OF CAFFEINE AND FUROSEMIDE USING DEEP EUTECTIC SOLVENTS FORMED BY CHOLINE CHLORIDE AND XYLITOL, CITRIC ACID, SORBITOL OR GLUCOSE, *

Also Published As

Publication number Publication date
PL249501B1 (pl) 2026-05-04

Similar Documents

Publication Publication Date Title
CN102858333A (zh) 呼吸紊乱的治疗
JP6764206B2 (ja) Ｏ−グリコシルフラボノイドの組成物
FI4545101T3 (fi) Stabiileja, väkevöityjä radionuklidikompleksiliuoksia
ES2605495T3 (es) Solución de atomoxetina
CN107961212A (zh) 一种控油抗菌洗发水
BR112017026202A2 (pt) composição modificadora da reologia seca, método de preparação da composição modificadora da reologia seca, formulação de produto e método de preparação de formulação
HRP20191019T1 (hr) Kombinacijska terapija konjugatom protutijela i lijeka anti-her2 i inhibitorom bcl-2
BR112017025527A2 (pt) preparação farmacêutica líquida, e, método para fabricar uma suspensão de celocoxibe.
TW519491B (en) Use of 1-hydroxy-2-pyridones for the treatment of saborrheic dermatitis
MX2023013266A (es) Solucion oral basada en citicolina y nicotinamida para usar en el tratamiento del glaucoma.
CN104257624A (zh) 一种新的泡腾崩解预混剂及其制备方法
JP2020535211A (ja) 医療用葉酸塩
RU2015145451A (ru) Препараты для местного применения, содержащие гиалуроновую кислоту, вербаскозид и глицерофосфоинозитол
BR112022004659A2 (pt) Métodos de tratamento com rifabutina, usos e composições
US10973919B2 (en) Vitamin preparation
HRP20231692T1 (hr) Postupak za suzbijanje gorčine derivata kinolina
PL249501B1 (pl) Sposób zwiększania rozpuszczalności kofeiny w roztworach wodnych
CN107865784A (zh) 一种基于协同美白作用的纳米级胶束爽肤水
EA201700226A1 (ru) Лекарственная композиция цитопротекторного действия в виде водного раствора для внутривенного введения и способ ее получения
TW201946628A (zh) 瑞博西尼琥珀酸鹽（Ｒｉｂｏｃｉｃｌｉｂ ｓｕｃｃｉｎａｔｅ ｓａｌｔ）晶型Ｂ、Ｃ及Ｄ與其衍生物，以及其等之製造方法與藥物組合物
JP2024529291A (ja) ウイルス感染症の処置および予防のための組成物および方法
RU2010136277A (ru) Галеновая форма для трансмукозально-буккального введения триптанов
EA201700072A1 (ru) Способ получения стабилизированной фармацевтической композиции в виде водного раствора
PL434153A1 (pl) Kompozycja zawierająca kannabinoidy
JP2017210428A (ja) ゼラチンカプセルおよび該ゼラチンカプセルの製造方法